图源:根据文献整理
[1] Clar C, Gill JA, Court R, Waugh N. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open 2012; 2. [2] ZinmanB, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortalityin Type2 Diabetes[J]. N Engl J Med, 2015, 373(22) : 2117-2128. [3] Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, et al. Canagliflozin and Cardiovascular and Renal Events inType2 Diabetes[J]. N Engl J Med, 2017, 377(7):644-657. [4] Wiviott SD, RazI, Bonaca MP, et al. DECLARE-TIMI58 Investigators.Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes [J] . N Engl J Med, 2019, 380(4):347-357. [5] 中国心力衰竭中心联盟专家委员会. 心力衰竭 SGLT2 抑制剂临床应用的中国专家共识 [J]. 临床心血管病杂志,2022,38(8) : 599-605 . [6] 2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults[J]. Elsevier Inc. 2022. 4.21 [7] Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials[J]. Lancet 2019; 393:31. [8] Kanie T, Mizuno A, Takaoka Y, et al. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis[J]. Cochrane Database Syst Rev 2021; 10:CD013650. [9] Foote C, Perkovic V, Neal B. Effects of SGLT2 inhibitors on cardiovascular outcomes[J]. Diab Vasc Dis Res 2012; 9:117. [10] Nyirjesy P, Zhao Y, Ways K, Usiskin K. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor[J]. Curr Med Res Opin 2012; 28:1173. [11] Invokana (canagliflozin). US FDA approved product information; Titusville, NJ: Janssen Pharmaceuticals, Inc; May 2016. |
|
来自: 浪迹天涯soyxqc > 《文件夹1》